Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Che-Leung Law

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 24, 2008
Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linkerEzogelin Oflazoglu, Ivan J Stone, Kristine Gordon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 26, 2011
Distinct apoptotic signaling characteristics of the anti-CD40 monoclonal antibody dacetuzumab and rituximab produce enhanced antitumor activity in non-Hodgkin lymphomaTimothy S Lewis, Renee S McCormick, Kim Emmerton, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 28, 2009
Blocking of CD27-CD70 pathway by anti-CD70 antibody ameliorates joint disease in murine collagen-induced arthritisEzogelin Oflazoglu, Tamar E Boursalian, Weiping Zeng, et al.
Molecular Cancer Therapeutics|September 29, 2023
Brentuximab Vedotin-Driven Microtubule Disruption Results in Endoplasmic Reticulum Stress Leading to Immunogenic Cell Death and Antitumor ImmunityRyan A Heiser, Anthony T Cao, Weiping Zeng, et al.
Cancer Research|February 28, 2016
Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical ModelsFu Li, Kim K Emmerton, Mechthild Jonas, et al.
Cancer Research|September 17, 2005
Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40Che-Leung Law, Kristine A Gordon, John Collier, et al.
Blood|October 14, 2006
Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activitiesJulie A McEarchern, Ezogelin Oflazoglu, Leigh Francisco, et al.
Mabs|January 13, 2010
Anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemiaMay Kung Sutherland, Changpu Yu, Timothy S Lewis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2008
Preclinical characterization of SGN-70, a humanized antibody directed against CD70Julie A McEarchern, Leia M Smith, Charlotte F McDonagh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2004
Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugatesChe-Leung Law, Charles G Cerveny, Kristine A Gordon, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 24, 2008
Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linkerEzogelin Oflazoglu, Ivan J Stone, Kristine Gordon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 26, 2011
Distinct apoptotic signaling characteristics of the anti-CD40 monoclonal antibody dacetuzumab and rituximab produce enhanced antitumor activity in non-Hodgkin lymphomaTimothy S Lewis, Renee S McCormick, Kim Emmerton, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 28, 2009
Blocking of CD27-CD70 pathway by anti-CD70 antibody ameliorates joint disease in murine collagen-induced arthritisEzogelin Oflazoglu, Tamar E Boursalian, Weiping Zeng, et al.
Molecular Cancer Therapeutics|September 29, 2023
Brentuximab Vedotin-Driven Microtubule Disruption Results in Endoplasmic Reticulum Stress Leading to Immunogenic Cell Death and Antitumor ImmunityRyan A Heiser, Anthony T Cao, Weiping Zeng, et al.
Cancer Research|February 28, 2016
Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical ModelsFu Li, Kim K Emmerton, Mechthild Jonas, et al.
Cancer Research|September 17, 2005
Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40Che-Leung Law, Kristine A Gordon, John Collier, et al.
Blood|October 14, 2006
Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activitiesJulie A McEarchern, Ezogelin Oflazoglu, Leigh Francisco, et al.
Mabs|January 13, 2010
Anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemiaMay Kung Sutherland, Changpu Yu, Timothy S Lewis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2008
Preclinical characterization of SGN-70, a humanized antibody directed against CD70Julie A McEarchern, Leia M Smith, Charlotte F McDonagh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2004
Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugatesChe-Leung Law, Charles G Cerveny, Kristine A Gordon, et al.
Pageof 3